November 30, 2017
11 am to 12 pm ET

Sponsored by

Webinar Description:

• Immuno-Oncology (IO) is one the major area in Oncology drug discovery with significant increase of Phase III clinical trial since the past 20 years and pivotal FDA-approved drugs
• Evotec has key expertise in the field further strengthened by internal IO programs and partnerships with clients
• Mologen is a key player in the field of Immunotherapies with lead compound in clinical development for first-line maintenance therapy in metastatic colorectal cancer (pivotal phase 3 IMPALA trial) and small-cell lung cancer (exploratory phase 2 IMPULSE trial)
• The webinar will provide an overview of Evotec’s offerings and collaborative work between Mologen & Evotec to generate IO data on the modulation of the tumour micro-environment, one crucial requirement for generating an anti-tumour effect and deciphering mechanism of action

Presenters:

Michaël Esquerré, PhD

Translational Biology
Group Leader Immuno-Oncology

Evotec

Dr Michael Esquerré has long been interested in the role of T lymphocytes subsets and in particular in regulatory T cells in mice and human. He started his science career by working on the use of regulatory T cells as a cell-based therapy to induce antigen-specific tolerance to medullar or solid organs allograft in preclinical murine models. His PhD research focused on the impact of human regulatory T cells on the formation of the immunological synapse between antigen-presenting cells and effector T cells. As a post-doctoral research fellow at INSERM, he worked on the molecular mechanisms regulating activation and polarization processes of T lymphocytes. In 2008, Dr Esquerré joined Genticel as Immunology Group Leader and was named Director of Immunology and Head of the R&D Immunology Department in 2012. He was responsible for preclinical R&D activities in Immuno-Oncology and patients immunomonitoring for therapeutic vaccine candidates from early preclinical to Phase II clinical stage products. The main target of these therapeutic vaccines was HPV-induced cancer. In 2015, Dr Esquerré has joined Evotec as Group Leader Immuno-Oncology. He is managing research teams dedicated to both Immuno-Oncology and Immunology & Inflammation fields. He and his group is bringing the expertise in Immunology for both internal R&D programs of Evotec and for R&D programs of external partners.

Manuel Schmidt

Director Translational Research
Senior Scientific Officer

MOLOGEN AG

Manuel Schmidt received his diploma degree in Chemistry from the Technical University of Berlin. He started his professional career in Clinical Research (Hematology/Oncology) in 1995 at University Hospital in Berlin, Dresden and Marburg, where he was responsible for leukemia research projects and the molecular diagnostic laboratory. He also received a scholarship to work at the Technion in Haifa, Israel. In 2000 he joined Mologen AG, being responsible for preclinical and clinical research on cancer immunotherapy. He brought product candidates into early clinical trials – one is currently in Phase 3 in colorectal carcinoma. Since 2013 he is – as Director of Translational Research – responsible for the development of new immunotherapeutic product candidates primarily in the oncological field and the translational strategy accompanying ongoing clinical trials.

Cost: No cost!

Schedule conflict? Register and you'll receive a copy of the recording!